Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Spratt

Showing results (381-390 of 498) with videos related to

Pageof 50
Sort By:
International Journal of Radiation Oncology, Biology, Physics|July 25, 2022
A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate CancerLiat Hammer, Ralph Jiang, Jason Hearn, et al.
JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.
The Lancet. Oncology|October 17, 2016
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysisShuang G Zhao, S Laura Chang, Daniel E Spratt, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.
Journal of the National Cancer Institute|October 16, 2018
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetShuang G Zhao, Jonathan Lehrer, S Laura Chang, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Cancer|April 15, 2023
A novel prostate cancer subtyping classifier based on luminal and basal phenotypesAdam B Weiner, Yang Liu, Alex Hakansson, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomyJoseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.
Practical Radiation Oncology|November 26, 2019
Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT TrialJohn L Gore, Marguerite du Plessis, Jingbin Zhang, et al.
Pageof 50

Showing results (381-390 of 498) with videos related to

Sort By:
Pageof 50
International Journal of Radiation Oncology, Biology, Physics|July 25, 2022
A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate CancerLiat Hammer, Ralph Jiang, Jason Hearn, et al.
JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.
The Lancet. Oncology|October 17, 2016
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysisShuang G Zhao, S Laura Chang, Daniel E Spratt, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.
Journal of the National Cancer Institute|October 16, 2018
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetShuang G Zhao, Jonathan Lehrer, S Laura Chang, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Cancer|April 15, 2023
A novel prostate cancer subtyping classifier based on luminal and basal phenotypesAdam B Weiner, Yang Liu, Alex Hakansson, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomyJoseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.
Practical Radiation Oncology|November 26, 2019
Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT TrialJohn L Gore, Marguerite du Plessis, Jingbin Zhang, et al.
Pageof 50